Loading…
Loading…
Novartis' pelacarsen study failed to cut cardiovascular events, clouding prospects for the drug and highlighting portfolio challenges.
AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.
Novartis said late Friday its Ionis-partnered Lp(a) blocker failed in testing. The results sent Novartis and Ionis stocks tumbling.
Ionis Pharmaceuticals and partner Novartis' experimental drug to lower high levels of a cholesterol-carrying particle in heart patients failed in a late-stage trial, the companies said on Friday.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared to placebo. Consistent with previous studies, substan.
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease Transcript
Ionis Pharmaceuticals NASDAQ: IONS said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive neurological disorder caused by pathogenic variants in the GFAP gene.
Ionis' FDA approval of Zanvastro marks the first disease-modifying treatment for Alexander disease and adds a priority review voucher.